Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. Cartherics will retain all the development and commercialisation rights for the therapy outside Greater China.

Gene Therapy 130

Gene Therapy Gene Development Clinical Trials 130

Pharmaceutical Technology

JULY 14, 2022

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). “The According to Kahn, this results in a need for improved and optimised commercialisation solutions across the industry.

Drugs 147

Drugs Medicine Marketing Development 147

Pharmaceutical Technology

NOVEMBER 9, 2022

CSL Behring has a commercialisation and license agreement to develop EtranaDez. million price tag. The post Can gene therapies for haemophilia defend their high price tags? A fair price for CSL Behring’s haemophilia B treatment etranacogene dezaparvovec would be between $2.93–2.96 million ($1.8 million at the time).

Gene Therapy 278

Gene Therapy Gene FDA Approval Medicine 278

Drug Discovery World

OCTOBER 31, 2022

Click’ chemistry used to tag proteins made by cancer cells. Merck (MSD) and Moderna have revealed plans to work together on the development and commercialisation of an investigational personalised cancer vaccine. A team from the University of Geneva (UNIGE) has found a way to overcome chemotherapy resistance in colorectal cancer.

Drugs 52

Drugs Research Gene Editing Protein 52

Drug Discovery World

DECEMBER 20, 2022

The clinical development of etranacogene dezaparvovec was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment. . World’s most expensive drug. A one-time treatment with etranacogene dezaparvovec costs US$3.5

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

Drug Discovery World

JULY 25, 2023

We have shown that the excipient does not only work for our SNAP-tag lipid (SNaP) LNP, but also for the commercialised vaccines. The excipient is listed in the pharmacopoeia as an inactive ingredient and therefore can easily added to an existing formulation.

Drugs 52

Drugs Packaging Packaging Manufacturing 52

pharmaphorum

MAY 10, 2022

The FDA awarded a fast-track designation to lecanemab in December and has also given the drug breakthrough tag as a treatment for early-stage Alzheimer’s, and Biogen and Eisai will be hoping the drug can sidestep the controversy that engulfed Aduhelm from the moment it was approved. The post Exit Aduhelm, enter lecanemab.

FDA Approval 40

FDA Approval Trials Clinical Trials Clinical Trials 40